CHMP recommends EU conditional approval of Roche’s antibody Mosunetuzumab for people with relapsed… EP News Bureau Apr 25, 2022 If approved, Mosunetuzumab would be the first CD20xCD3 T-cell engaging bispecific antibody available to treat Follicular Lymphoma…